Visit Canaloplasty.com
Visit Nova-Eye.com
us
Global Germany United States

Lighting the way 
in canaloplasty.

The iTrack™ Advance Advantage

For over a decade, Nova Eye’s proprietary iTrack™ canaloplasty microcatheter has been used across the globe to effectively treat more than 120,000 glaucoma patients.* Building on this proven track record, we are proud to introduce the next generation of iTrack™ – iTrack™ Advance.

The ground-breaking iTrack™ Advance takes the established effectiveness,1 accuracy and reliability of the original iTrack™ canaloplasty microcatheter and combines it with an ergonomic, easy-to-use handheld injector.

The iTrack™ Advance has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. 

The iTrack ™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma. 

CANALOPLASTY IN YOUR HANDS

Developed out of extensive research, innovation and feedback from surgeons, the iTrack™ Advance’s all-in-one handheld injector allows for streamlined insertion of the microcatheter into Schlemm’s canal. It also enables predictable, controlled and smooth advancement/​retraction of the microcatheter through the canal. The clinically proven1 iTrack™ microcatheter is at the heart of the iTrack™ Advance. Measuring just 200 microns in diameter, it comprises a sophisticated set of inner workings including a proprietary fiber optic for illuminating the distal tip.

Cannula

Spatulated tip design for ease of access into Schlemm's canal.

Nozzle

Nozzle can be rotated 360° to precisely position the cannula.

Actuator

Smooth gliding mechanism for precise advancement and retraction of microcatheter during canal intubation and withdrawal.

Polymer Shaft

220-micron shaft with lubricious coating for 360° cannulation of Schlemm’s canal.

Infusion Pathway

Infusion pathway that connects to ViscoInjector™ OVD delivery system.

Guidewire Mechanism

Internal guidewire to push through adhesions and to move through tight areas or structures of the canal.

Optical Fiber

Optical Fiber connects to the portable iLumin™ light source.

Illuminated Tip

Proprietary illuminated tip for transluminal visualization of the microcatheter through every procedural step.

Real Canaloplasty with the iTrack™ Advance

The unique design of the iTrack™ Advance allows you to perform Real Canaloplasty. That is, canaloplasty performed over the entire 360º of the conventional outflow pathway via a single intubation. Utilizing a process of catheterization and pressurized viscodilation, iTrack™ Advance is designed to stretch the trabecular meshwork and create microperforations into the anterior chamber, and to remove herniations of the collector channel ostia.2,3,4

Ultimately, it’s canaloplasty without compromise.

+100 MICROLITERS OF OVD +100 MICROLITERS OF OVD

iTrack™ Advance delivers 100+ microliters of OVD* over 360° of the canal.*

* Testing using a robotically controlled ViscoInjector™ with time-recording mass data to simulate the delivery of OVD over 360° of Schlemm’s canal. Data available upon request.

PRESSURIZED VISCODILATION

iTrack™ Advance delivers OVD into Schlemm’s canal via a patented, pressurized mechanism (Patent No. US7,967,772,B2).

360 degree canaloplasty

With a flexible design and internal guide-wire, iTrack™ Advance can catheterize and viscodilate 360° of the canal in a single intubation

ILLUMINATED CANALOPLASTY

A proprietary illuminated fiber optic tip to the microcatheter provides continuous location feedback and safeguards against misdirection of the iTrack™ Advance into the suprachoroidal space or the collector channels.

Canaloplasty for stent-free, tissue-sparing glaucoma treatment

Inspired by the success and methodology of modern angioplasty, Nova Eye pioneered canaloplasty for glaucoma in 2008 with the launch of the rigorously tested iTrack™ procedure, which combines 360° catheterization and pressurized viscodilation to treat all points of outflow resistance.1 Stent-free and tissue-preserving, canaloplasty can help glaucoma surgeons, comprehensive ophthalmologists and cataract specialists effectively reduce IOP in cases of mild to moderate glaucoma, while preserving the viability of future treatment options. 

As a 360° procedure that addresses the entire conventional outflow pathway, including the trabecular meshwork, Schlemm’s canal and the collector channels,2,3,4 iTrack™ Advance literally treats glaucoma from all angles.

What’s more, iTrack™ Advance is cleared for use as a standalone procedure and in combination with cataract surgery.

By maintaining the natural pathway of aqueous outflow, iTrack™ Advance lets you work with patient physiology, not against it.

1. Khaimi, M. A., Dvorak, J. D., & Ding, K. (2017). An analysis of 3‑year outcomes following canaloplasty for the treatment of open-angle glaucoma. Journal of ophthalmology, 2017.
2. Smit BA, Johnstone MA. Effects of viscoelastic injection into Schlemm’s canal in primate and human eyes: potential relevance to viscocanalostomy. Ophthalmology. 2002;109(4):786 – 792.3. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316 – 322.4. Johnstone MA, Grant WM. Microsurgery of Schlemm’s canal and the human aqueous outflow system. Am J Ophthalmol 1973;76:906 – 17.* Company estimate based on sales figures for the iTrack™ canaloplasty microcatheter from 2008 – 2022. 

The iTrack™ Advance has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.  Indications for Use, USA: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The ab interno surgical technique is not a cleared indication for the iTrack™ Advance in the USA. * The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma. Indications for Use, International: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. CONTRAINDICATIONS: The Nova Eye iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal. WARNINGS: Do not use the cannula to create an incision in the cornea or other external tis​sues​. Be careful when taking off the protective cap of the Cannula to not break sterility by piercing the surgical drapes or gloves of the Surgeon or technicians with the exposed Cannula. The fiber optic line and infusion lines must not be pulled as these lines are attached to the back end of the iTrack™ Advance Handle when in use. PRECAUTIONS: Do not use product if the tamper proof seal has been broken. Do not use product if the pouch integrity has been broken. Do not remove the protective cover from the Cannula until ready to use. Handle the iTrack™ Advance carefully to avoid damaging the device. Do not use product if the cannula cover is not attached to the handpiece. Do not pull the black fiber optic line or grab onto the hub until the assembly has been fully removed from the packaging to avoid damage. Do not apply excessive force to the cannula cover or the actuator. Do not let the viscoelastic dry at the tip of the microcatheter, as this can cause the lumen to become occluded. Ensure the fiber optic line is not in a path that can be pulled or tripped on. Avoid touching the Cannula with any surfaces as this may damage the precisely manufactured spatulated tip. Do not bend cannula. Do not use excessive force when directing the Cannula and maintain visualization of the spatulated tip to avoid contacting unintended tissues. Do not use excessive force when directing the Cannula and maintain visualization of the Spatulated Tip and microcatheter to avoid contacting and damaging unintended tissues. The microcatheter should be advanced slowly and the spatulated tip must be positioned correctly to prevent the microcatheter from being kinked or bent. Actuator withdrawal and viscoelastic flow must be smooth, consistent, and continuous. If the microcatheter does not move forward and out of the cannula then discard the iTrack System and proceed to use another device. When applicable, remove excess viscoelastic from the eye by irrigation and/​or aspiration. POTENTIAL ADVERSE EVENTS: All of the fluid and tissue contact materials used in the iTrack™ Advance are well tolerated in human and animal studies. Possible adverse events with the use of the iTrack™ Advance include, but are not limited to, the following: Hyphema; Elevated IOP ; Descemet’s membrane detachment; Shallow or flat anterior chamber; Hypotony; Trabecular meshwork rupture; Choroidal effusion; Peripheral anterior synechiae; Iris prolapse; Pupil displacement; Suprachoroidal hemorrhage; Astigmatism; Inadvertent bleb.

READY TO LEARN MORE ABOUT ITRACK™ ADVANCE?

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More